NCT00387946CompletedPhase 3
An International, Seven-week, Double-blind, Placebo-controlled, Two Parallel Group Study to Assess the Efficacy of Dianicline 40 mg Bid as an Aid to Smoking Cessation in Cigarette Smokers
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Sanofi
- Enrollment
- 630
- Locations
- 2
- Primary Endpoint
- To assess the continuous abstinence from tobacco smoking at every visit during the last 4 weeks of treatment period, i.e. from week 4 to week 7, through direct inquiry of patients, exhaled carbon monoxide (CO) testing, and plasma cotinine measurements
Study Overview
Brief Summary
The primary study objective is to demonstrate the efficacy of dianicline as an aid to smoking cessation in cigarette smokers. The main secondary objectives are to assess the: craving for cigarettes, nicotine withdrawal symptoms, and safety of dianicline.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Outpatients, over legal age, smoking at least 10 cigarettes/day as a mean within the 2 months preceding the screening visit.
Exclusion Criteria
- •Patients who have taken an investigational drug within the past six months prior to the screening visit.
- •Patients who had a previous quit attempt (= or >1 day with the aid of pharmacological adjunct) in the previous three months (before screening).
- •Patients who have smoked or consumed non-tobacco cigarettes or any form of tobacco product (other than cigarettes such as cigars, pipes, smokeless tobacco, etc) more than 3 times within the 3 months preceding the screening visit.
- •Patients who currently present with (based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition [DSM-IV]):
- •Psychotic disorder
- •Major depressive episode
- •Pregnant or breast-feeding women.
- •Women of childbearing potential not protected by effective contraceptive method of birth control and/or who are unwilling or unable to be tested for pregnancy. Medically acceptable methods of birth control for this study include approved hormonal contraceptive medications or devices, approved intra-uterine contraceptive devices, use of two combined barrier methods.
- •Patients who have suffered from a myocardial infarction, unstable angina or other major cardiovascular event within the past week prior to screening.
- •Patients who have a history of multiple allergic reactions to medications in two drug classes.
- •Patients who have QTcF > 500 ms on the electrocardiogram (ECG).
- •Patients with mild, moderate or severe renal impairment.
- •Patients who have an abnormal laboratory test of potential clinical significance at screening.
Outcomes
Primary Outcomes
To assess the continuous abstinence from tobacco smoking at every visit during the last 4 weeks of treatment period, i.e. from week 4 to week 7, through direct inquiry of patients, exhaled carbon monoxide (CO) testing, and plasma cotinine measurements
Secondary Outcomes
- Questionnaire of Smoking Urges to assess craving for cigarettes; Hughes and Hatsukami Minnesota Withdrawal Scale to measure nicotine withdrawal, number of smoke-free days, and average number of cigarettes smoked from smoking status interview
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 3
Efficacy and Safety of Dianicline Versus Placebo as an Aid to Smoking CessationSmokingNCT00356967Sanofi602
Completed
Phase 4
Clinical Trial to Evaluate the Efficacy of Smoking CessationSmoking CessationNCT01538394Josep Maria Ramon Torrell, PhD322
Completed
Phase 4
Smoking Cessation Study In Healthy Adolescent SmokersSmoking CessationNCT01312909Pfizer312
Recruiting
Not Applicable
Nicotine Replacement Therapy Sampling for Smokers in the CommunityTobacco SmokingNCT05881083The University of Hong Kong1,014
Completed
Phase 4
Effectiveness of Varenicline: Testing Individual DifferencesSmoking AddictionNCT01228175The Mind Research Network218